Purchase

Recombinant Human TGF beta 1 protein (His Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

His Tag

Activity

not tested

Cat no : Eg0879


Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Human TGF beta 1 protein Leu30-Ser390 (Accession# P01137) with a His tag at the C-terminus.
GeneID 7040
Accession P01137
PredictedSize 42.3 kDa
SDS-PAGE 14 kDa, 35-40 kDa and 47-60 kDa, reducing (R) conditions
Formulation Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

TGF-beta is a member of the transforming growth factor beta (TGFB) family of cytokines, which are multifunctional peptides that regulate proliferation, differentiation, adhesion, migration, and other functions in many cell types. TGF-beta is produced by a number of cell types including regulatory T cells, fibroblasts, epithelial cells, and endothelial cells. TGF-beta acts synergistically with TGFA in inducing transformation. It also acts as a negative autocrine growth factor. TGF-beta plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. Mice lacking TGF-beta develop severe multifocal inflammatory disease, yolk sac defects and colon cancer.

References:

1. Siegel PM. et al. (2003) Nat Rev Cancer 3: 807-21. 2. Bierie B. et al. (2006) Nat Rev Cancer 6: 506-20. 3. Tian M. et al. (2009) Future Oncol 5: 259-71. 4. Priyadarshi S. et al. (2013) 28: 2490-7.